Search

Start Over Keyword Adenovirus 5

  • Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals.

    Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals.
    Authors:Jonathan D Fuchs, San Francisco Department of Public HealthPierre-Alexandre Bart, Centre Hospitalier Universitaire VaudoisNicole Frahm, Fred Hutchinson Cancer Research CenterCecilia Morgan, Fred Hutchinson Cancer Research CenterPeter B Gilbert, Fred Hutchinson Cancer Research CenterNidhi Kochar, Fred Hutchinson Cancer Research CenterStephen C DeRosa, Fred Hutchinson Cancer Research CenterGeorgia D Tomaras, Duke UniversityTheresa M Wagner, San Francisco Department of Public HealthLindsey R Baden, Brigham and Women's HospitalBeryl A Koblin, New York Blood CenterNadine Rouphael, Emory UniversitySpyros A Kalams, Vanderbilt UniversityMichael C Keefer, University of RochesterPaul A Goepfert, University of Alabama at BirminghamMagdalena E Sobieszczyk, Columbia UniversityKenneth H Mayer, Harvard UniversityEdith Swann, National Institute of Allergy and Infectious DiseasesHua-Xin Liao, Duke UniversityBarton F Haynes, Duke UniversityBarney S Graham, National Institute of Allergy and Infectious DiseasesM Juliana McElrath, Fred Hutchinson Cancer Research CenterHIV/AIDS Clinical Trials Network, National Institute of Allergy and Infectious Diseases
    Date:2015
    Publisher:OMICS International
    Publication Version:Final Published Version
    License:Creative Commons Attribution 4.0 International